- Home
- HLP vs IPSC Comparison
HLP vs IPSC Comparison
Compare HLP & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- IPSC
- Stock Information
- Founded
- HLP 2021
- IPSC 2019
- Country
- HLP China
- IPSC United States
- Employees
- HLP N/A
- IPSC N/A
- Industry
- HLP Industrial Machinery/Components
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- HLP Industrials
- IPSC Health Care
- Exchange
- HLP Nasdaq
- IPSC Nasdaq
- Market Cap
- HLP 52.1M
- IPSC 42.2M
- IPO Year
- HLP 2023
- IPSC 2021
- Fundamental
- Price
- HLP $0.69
- IPSC $0.51
- Analyst Decision
- HLP
- IPSC Strong Buy
- Analyst Count
- HLP 0
- IPSC 5
- Target Price
- HLP N/A
- IPSC $3.33
- AVG Volume (30 Days)
- HLP 207.2K
- IPSC 705.0K
- Earning Date
- HLP 09-18-2025
- IPSC 08-14-2025
- Dividend Yield
- HLP N/A
- IPSC N/A
- EPS Growth
- HLP N/A
- IPSC N/A
- EPS
- HLP N/A
- IPSC N/A
- Revenue
- HLP $14,105,620.00
- IPSC $114,128,000.00
- Revenue This Year
- HLP N/A
- IPSC $1,589.94
- Revenue Next Year
- HLP N/A
- IPSC N/A
- P/E Ratio
- HLP N/A
- IPSC N/A
- Revenue Growth
- HLP N/A
- IPSC 5491.77
- 52 Week Low
- HLP $0.61
- IPSC $0.34
- 52 Week High
- HLP $2.13
- IPSC $1.86
- Technical
- Relative Strength Index (RSI)
- HLP 48.54
- IPSC 41.97
- Support Level
- HLP $0.66
- IPSC $0.50
- Resistance Level
- HLP $0.68
- IPSC $0.55
- Average True Range (ATR)
- HLP 0.05
- IPSC 0.04
- MACD
- HLP 0.01
- IPSC -0.00
- Stochastic Oscillator
- HLP 40.08
- IPSC 32.78
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.